As of 2025-07-08, the Intrinsic Value of Tekla Healthcare Investors (HQH) is 47.39 USD. This HQH valuation is based on the model Discounted Cash Flows (Growth Exit 5Y). With the current market price of 15.58 USD, the upside of Tekla Healthcare Investors is 204.20%.
The range of the Intrinsic Value is 41.65 - 55.21 USD
Based on its market price of 15.58 USD and our intrinsic valuation, Tekla Healthcare Investors (HQH) is undervalued by 204.20%.
| Range | Selected | Upside | |
| a | |||
| DCF (Growth 5y) | 41.65 - 55.21 | 47.39 | 204.2% |
| DCF (Growth 10y) | 55.15 - 72.44 | 62.49 | 301.1% |
| DCF (EBITDA 5y) | 77.25 - 102.55 | 88.03 | 465.0% |
| DCF (EBITDA 10y) | 90.99 - 122.91 | 104.59 | 571.3% |
| Fair Value | 85.87 - 85.87 | 85.87 | 451.16% |
| P/E | 15.66 - 17.93 | 16.36 | 5.0% |
| EV/EBITDA | (0.13) - 87.83 | 35.71 | 129.2% |
| EPV | (0.36) - (0.42) | (0.39) | -102.5% |
| DDM - Stable | 18.54 - 32.65 | 25.60 | 64.3% |
| DDM - Multi | 18.96 - 26.43 | 22.11 | 41.9% |
| Market Cap (mil) | 839.14 |
| Beta | 3.55 |
| Outstanding shares (mil) | 53.86 |
| Enterprise Value (mil) | 839.14 |
| Market risk premium | 4.60% |
| Cost of Equity | 11.72% |
| Cost of Debt | 5.00% |
| WACC | 7.69% |